Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight

globenewswire.com
BIIB Biogen's drug MOR202 (felzartamab) is listed as an emerging therapy for Idiopathic Membranous Nephropathy, suggesting potential for market expansion and positive revenue contribution. VRTX Vertex Pharmaceuticals' drug ALPN-303 (povetacicept) is highlighted for its dual-action inhibition and advanced clinical development for Idiopathic Membranous Nephropathy, indicating strong potential for market impact and growth. AZN AstraZeneca's drug ALXN1920 is mentioned as an emerging therapy for Idiopathic Membranous Nephropathy, suggesting potential for market growth and positive future prospects. VTRS Vera Therapeutics' drug Atacicept is listed as an emerging therapy for Idiopathic Membranous Nephropathy, indicating potential for market expansion and positive future revenue streams. NKTR Nkarta, Inc.'s drug NKX019 is mentioned as an emerging therapy for Idiopathic Membranous Nephropathy, suggesting potential for market growth and positive future contributions. CLMB Climb Bio's drug Budoprutug is listed as an emerging therapy for Idiopathic Membranous Nephropathy, indicating potential for market expansion and positive future revenue.

Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight New York, USA, April 06, 2026 (GLOBE NEWSWIRE) -- Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight

The idiopathic membranous nephropathy market is poised for steady expansion driven by rising disease prevalence, enhanced diagnostic capabilities, and increased adoption of supportive and emerging targeted therapies such as SNP-ACTH (1-39) Gel (Cerium Pharmaceuticals), BRUKINSA (zanubrutinib) (BeiGene), GAZYVA (obinutuzumab) (Hoffmann-La Roche), MOR202 (felzartamab) (Biogen), Budoprutug (Climb Bio), and others.

Recently published Idiopathic Membranous Nephropathy Market Insights report includes a comprehensive understanding of current treatment practices, idiopathic membranous nephropathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Idiopathic Membranous Nephropathy Market Summary

Discover which idiopathic membranous nephropathy medications are expected to grab the market share @ https://www.delveinsight.com/sample-request/idiopathic-membranous-nephropathy-market

Key Factors Driving the Growth of the Idiopathic Membranous Nephropathy Market

According to Stuti Mahajan, consulting manager at DelveInsight, “emerging biomarkers and novel therapeutic targets continue to reshape the MN treatment landscape, offering potential for more precise disease monitoring, improved prediction of treatment response, and the development of safer, more effective targeted therapies.”

Idiopathic Membranous Nephropathy Market Analysis

Learn more about the idiopathic membranous nephropathy treatment options @ Idiopathic Membranous Nephropathy Treatment Market

Idiopathic Membranous Nephropathy Competitive Landscape

Some of the IMN drugs under clinical trials include SNP-ACTH (1-39) Gel (Cerium Pharmaceuticals), BRUKINSA (zanubrutinib) (BeiGene), GAZYVA (obinutuzumab) (Hoffmann-La Roche), MOR202 (felzartamab) (Biogen), ALPN-303 (povetacicept) (Vertex Pharmaceuticals Incorporated/Ono Pharmaceuticals), WAL0921 (Walden Bioscience), ALXN1920 (AstraZeneca), Budoprutug (Climb Bio), Resomelagon (AP1189) (SynAct Pharma ApS), Atacicept (Vera Therapeutics), NKX019 (Nkarta, Inc.), and others.

Cerium has developed a subcutaneous synthetic porcine ACTH therapy, SNP-ACTH (1–39) Gel, aimed at delivering accurate and consistent ACTH dosing to enhance treatment outcomes in primary membranous nephropathy. Preclinical findings indicate strong safety and efficacy, while a Phase I study in healthy volunteers confirmed favorable safety and tolerability. The company is now moving into a Phase III randomized study, in collaboration with the FDA, to assess whether SNP-ACTH (1–39) Gel can outperform rituximab in achieving durable proteinuria remission as a first-line therapy for patients at moderate to high risk. Patient enrollment for this Phase III trial is currently underway.

Vertex/Ono Pharmaceuticals’ Povetacicept is a dual-action inhibitor targeting the BAFF and APRIL cytokines, both of which are involved in B-cell activation, differentiation, and survival, thereby contributing to the development of various autoimmune conditions. By blocking these pathways, the therapy helps regulate B-cell activity. Its engineered TACI domain has shown enhanced binding affinity, potency, and tissue penetration in preclinical studies compared to other BAFF, APRIL, or combined inhibitors. The drug is presently in Phase II/III clinical development for the treatment of primary membranous nephropathy.

The anticipated launch of these emerging idiopathic membranous nephropathy therapies are poised to transform the idiopathic membranous nephropathy market landscape in the coming years. As these cutting-edge idiopathic membranous nephropathy therapies continue to mature and gain regulatory approval, they are expected to reshape the idiopathic membranous nephropathy market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about new treatment for idiopathic membranous nephropathy, visit @ Idiopathic Membranous Nephropathy Medication

Recent Developments in the Idiopathic Membranous Nephropathy Market

What is Idiopathic Membranous Nephropathy?

Idiopathic membranous nephropathy (IMN) is a chronic autoimmune kidney disorder in which the body’s immune system mistakenly targets the filtering units of the kidneys, known as glomeruli. The disease is characterized by the formation of immune complexes along the glomerular basement membrane, leading to thickening of this membrane and impaired kidney filtration. As a result, patients often develop nephrotic syndrome, marked by heavy protein loss in the urine, low blood albumin levels, swelling, and increased risk of blood clots and infections. In most cases, IMN is driven by autoantibodies, most commonly against the phospholipase A2 receptor (PLA2R), and occurs without an identifiable secondary cause such as infection, malignancy, or systemic autoimmune disease. The clinical course is variable, ranging from spontaneous remission to progressive loss of kidney function over time.

Idiopathic Membranous Nephropathy Epidemiology Segmentation

The idiopathic membranous nephropathy epidemiology section provides insights into the historical and current idiopathic membranous nephropathy patient pool and forecasted trends for the leading markets. In the US, a consistently higher number of cases are projected to be reported in the late-onset group. The number of cases of PLA2R and THSD7A antigen-specific Idiopathic Membranous Nephropathy were nearly 20,000 and 800, respectively, in 2025.

The idiopathic membranous nephropathy market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:

Download the report to understand idiopathic membranous nephropathy management @ Idiopathic Membranous Nephropathy Treatment Options

Scope of the Idiopathic Membranous Nephropathy Market Report

Discover more about idiopathic membranous nephropathy drugs in development @ Idiopathic Membranous Nephropathy Clinical Trials

Table of Contents

Related Reports

Idiopathic Membranous Nephropathy Epidemiology

Idiopathic Membranous Nephropathy Epidemiology Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted IMN epidemiology in the 7MM, i.e., the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

BTK Inhibitors Market

BTK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key BTK inhibitors companies, including BeiGene, Nurix Therapeutics, Roche, Genentech, Sanofi, Principia Pharma, Novartis, ACEA Therapeutics, InnoCare Pharma, and others.

IgA Nephropathy Market

IgA Nephropathy Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key IgAN companies including Novartis, F. Hoffmann-La Roche, Ionis Pharmaceuticals, AstraZeneca (Alexion Pharmaceuticals), Vertex Pharmaceuticals, Otsuka Pharmaceutical, Biogen, Arrowhead Pharmaceuticals, NovelMed, Q32 Bio, Walden Biosciences, Takeda Pharmaceutical, Vera Therapeutics, and others.

Focal Segmental Glomerulosclerosis Market

Focal Segmental Glomerulosclerosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key focal segmental glomerulosclerosis companies, including ACELYRIN Inc., Genentech, Inc., ChemoCentryx, Travere Therapeutics, Inc., River 3 Renal Corp., Boehringer Ingelheim, Dimerix Bioscience Pty Ltd, Chinook Therapeutics, Inc., Aldeyra Therapeutics, Inc., and others.

Nephrotic Syndrome Market

Nephrotic Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key nephrotic syndrome companies including Vertex Pharmaceuticals, Chinook Therapeutics, Novartis, Boehringer Ingelheim, Hoffmann-La Roche, Biogen, Cerium Pharmaceuticals, Otsuka Pharmaceutical Development & Commercialization, Visterra, Ionis Pharmaceuticals, Kezar Life Sciences, Alpine Immune Sciences, Dimerix Bioscience, Advanz Pharma, Apellis Pharmaceuticals, Vera Therapeutics, Inc., AstraZeneca, HI-Bio, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.